PE20051051A1 - Compuestos de triazol como antagonistas de la vasopresina - Google Patents

Compuestos de triazol como antagonistas de la vasopresina

Info

Publication number
PE20051051A1
PE20051051A1 PE2005000032A PE2005000032A PE20051051A1 PE 20051051 A1 PE20051051 A1 PE 20051051A1 PE 2005000032 A PE2005000032 A PE 2005000032A PE 2005000032 A PE2005000032 A PE 2005000032A PE 20051051 A1 PE20051051 A1 PE 20051051A1
Authority
PE
Peru
Prior art keywords
triazol
phenyl
ilmethyl
methanone
piperidin
Prior art date
Application number
PE2005000032A
Other languages
English (en)
Inventor
Lee Richard Roberts
Justin Stephen Bryans
Thomas Ryckmans
Patrick Stephen Johnson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0329693A external-priority patent/GB0329693D0/en
Priority claimed from GB0408789A external-priority patent/GB0408789D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PE20051051A1 publication Critical patent/PE20051051A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE TRIAZOL DE FORMULA (I), EN DONDE X ES -[CH2]a-R O -[CH2]a-O-[CH2]b-R; EN DONDE a Y b ES DE 0 A 6; R ES H, CF3 O Het, EL CUAL ES HETEROCICLICO DE 5 A 6 MIEMBROS CON ATOMOS DE O, S Y N OPCIONALMENTE SUSTITUIDOS; Y ES UNO O MAS SUSTITUYENTES, INDEPENDIENTES ENTRE SI, -[O]c-[CH2]d-R1; DONDE R1 ES H, HALO, CF3, CN O Het1; V ES UN ENLACE DIRECTO O -O-; Q ES UN ENLACE DIRECTOS O -N(R2)-; EL ANILLO A ES HETEROCICLICO SATURADO DE 5 A 7 MIEMBROS, COMO PIPERIDINIL; Z ES -[O]e-[CH2]f-R3, FENILO O Het3, OPCIONALMENTE SUSTITUIDOS. SON COMPUESTOS PREFERIDOS: {4-[4-(4-CLORO-FENIL)-5-[1,2,3]TRIAZOL-1-2-ILMETIL-4H-[1,2,4,TRIAZOL-3-IL]-PIPERIDIN-1-IL}-(3,5-DIFLUORO-FENIL)-METANONA, {4-[4-(4-CLORO-FENIL)-5-[1,2,3]TRIAZOL-1-2-ILMETIL-4H-[1,2,4,TRIAZOL-3-IL]-PIPERIDIN-1-IL}-(3-FLUORO-FENIL)-METANONA, {4-[4-(4-CLORO-FENIL)-5-[1,2,3]TRIAZOL-1-2-ILMETIL-4H-[1,2,4,TRIAZOL-3-IL]-PIPERIDIN-1-IL}-(2,3-DIFLUORO-FENIL)-METANONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ADEMAS PUEDE PRESENTARSE EN COMBINACION CON OTRO AGENTE ACTIVO COMO UN ANTICONCEPTIVO ORAL, INHIBIDOR DE COX, INHIBIDOR PDEV, DONADOR NO O L-ARGININA. ESTOS COMPUESTOS SON ANTAGONISTAS DE LA VASOPRESINA, EN PARTICULAR DEL RECEPTOR V1 Y SON UTILES EN EL TRATAMIENTO DE LA DISMENORREA (PRIMARIA O SECUNDARIA)
PE2005000032A 2003-12-22 2005-01-03 Compuestos de triazol como antagonistas de la vasopresina PE20051051A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0329693A GB0329693D0 (en) 2003-12-22 2003-12-22 Compounds useful in therapy
GB0408789A GB0408789D0 (en) 2004-04-20 2004-04-20 Triazole derivatives

Publications (1)

Publication Number Publication Date
PE20051051A1 true PE20051051A1 (es) 2005-12-17

Family

ID=34740750

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000032A PE20051051A1 (es) 2003-12-22 2005-01-03 Compuestos de triazol como antagonistas de la vasopresina

Country Status (25)

Country Link
EP (1) EP1701959A1 (es)
JP (1) JP4698604B2 (es)
KR (1) KR100854872B1 (es)
AP (1) AP2331A (es)
AR (1) AR047340A1 (es)
AU (1) AU2004309164B2 (es)
BR (1) BRPI0417267A (es)
CA (1) CA2551038C (es)
CR (1) CR8481A (es)
DO (1) DOP2004001062A (es)
EA (1) EA010132B1 (es)
EC (1) ECSP066647A (es)
GE (1) GEP20084571B (es)
HK (1) HK1095822A1 (es)
IL (1) IL176349A (es)
IS (1) IS8472A (es)
MA (1) MA28393B1 (es)
NL (1) NL1027833C2 (es)
NO (1) NO20063380L (es)
OA (1) OA13347A (es)
PA (1) PA8620501A1 (es)
PE (1) PE20051051A1 (es)
TW (1) TWI287541B (es)
UY (1) UY28693A1 (es)
WO (1) WO2005063754A1 (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
JP5043668B2 (ja) 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
TW200626154A (en) * 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7923563B2 (en) 2004-10-26 2011-04-12 Eisai R&D Management Co., Ltd. Amorphous object of cinnamide compound
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
MX2007015216A (es) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
EP1917255A2 (en) * 2005-07-29 2008-05-07 F. Hoffmann-Roche AG Indol-3-yl-carbonyl-piperidin and piperazin derivatives
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
WO2008013622A2 (en) * 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
US9090604B2 (en) 2006-07-27 2015-07-28 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
AR062095A1 (es) 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
AU2007329066B2 (en) * 2006-12-07 2012-04-12 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives
WO2008068185A1 (en) * 2006-12-07 2008-06-12 F. Hoffmann-La Roche Ag Spiro-piperidine derivatives as via receptor antagonists
US7501432B2 (en) * 2006-12-22 2009-03-10 Hoffman-La Roche Inc. Spiro-piperidine derivatives
ATE486877T1 (de) * 2006-12-29 2010-11-15 Hoffmann La Roche Azaspiroderivate
CL2008000582A1 (es) 2007-02-28 2008-06-27 Eisai R&D Man Co Ltd Compuestos ciclicos derivados de oximorfolina condensados; farmacos que comprenden a dichos compuestos; y su uso para tratar enfermedad de alzheimer, demencia senil, sindrome de down o amiloidosis.
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
TW200916469A (en) 2007-08-31 2009-04-16 Eisai R & Amp D Man Co Ltd Multi-cyclic compounds
EP2358202B1 (en) * 2008-11-03 2016-06-15 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
EP2623499B1 (en) 2010-10-01 2015-04-22 Taisho Pharmaceutical Co., Ltd 1,2,4-triazolone derivative
US9447025B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
CN105814013A (zh) 2013-12-12 2016-07-27 卡利拉制药公司 双环烷基化合物及合成
JP6741343B2 (ja) 2014-03-07 2020-08-19 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー プロペラン誘導体および合成
JP6833677B2 (ja) * 2014-09-17 2021-02-24 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 二環式化合物
US10138236B2 (en) 2014-09-24 2018-11-27 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
MA40893B1 (fr) * 2014-11-03 2018-11-30 Bayer Pharma AG Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
RU2637101C2 (ru) * 2016-01-11 2017-11-29 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр вирусологии и микробиологии" (ФГБНУ ФИЦВиМ) Устройство для определения аспирированной дозы аэрозолей
EP3419626A1 (en) * 2016-02-23 2019-01-02 Servicio Andaluz De Salud Piperazine derivatives as antiviral agents with increased therapeutic activity
AR108263A1 (es) 2016-05-03 2018-08-01 Bayer Pharma AG Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
US10525041B2 (en) 2016-05-03 2020-01-07 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
EP3452457B1 (en) 2016-05-03 2020-03-18 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
US20190119251A1 (en) 2016-05-03 2019-04-25 Bayer Pharma Aktiengesellschaft Amide-substituted aryltriazole derivatives and uses thereof
WO2017191114A1 (en) 2016-05-03 2017-11-09 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
JP6710273B2 (ja) * 2016-05-09 2020-06-17 日本曹達株式会社 環状アミン化合物および有害生物防除剤
US10927098B2 (en) 2016-10-20 2021-02-23 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted triazole derivatives and uses thereof
CA3063729A1 (en) 2017-05-15 2018-11-22 Recurium Ip Holdings, Llc Analgesic compounds
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
WO2019081306A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
US11149023B2 (en) 2017-10-24 2021-10-19 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
CA3084308A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Substituted triazole derivatives and uses thereof
AU2018356352A1 (en) 2017-10-24 2020-04-16 Bayer Aktiengesellschaft Prodrugs of substituted triazole derivatives and uses thereof
CA3084411A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
CA3079770A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481360A (en) * 1983-08-26 1984-11-06 The Upjohn Company 4H-1,2,4-Triazol-3-yl compounds
WO2001058880A1 (fr) * 2000-02-08 2001-08-16 Yamanouchi Pharmaceutical Co., Ltd. Derives de triazole
CA2409819C (en) * 2000-05-19 2009-09-15 Yamanouchi Pharmaceutical Co., Ltd. Triazole derivatives

Also Published As

Publication number Publication date
HK1095822A1 (en) 2007-07-06
BRPI0417267A (pt) 2007-04-17
NL1027833A1 (nl) 2005-06-23
JP4698604B2 (ja) 2011-06-08
CR8481A (es) 2007-12-04
NO20063380L (no) 2006-09-22
PA8620501A1 (es) 2005-08-04
DOP2004001062A (es) 2005-06-30
KR20060101546A (ko) 2006-09-25
IS8472A (is) 2006-05-18
JP2007515468A (ja) 2007-06-14
TW200528099A (en) 2005-09-01
CA2551038A1 (en) 2005-07-14
TWI287541B (en) 2007-10-01
EA200600925A1 (ru) 2006-12-29
AP2006003631A0 (en) 2006-06-30
EP1701959A1 (en) 2006-09-20
MA28393B1 (fr) 2007-01-02
AU2004309164B2 (en) 2007-11-15
ECSP066647A (es) 2006-10-25
EA010132B1 (ru) 2008-06-30
IL176349A (en) 2011-11-30
GEP20084571B (en) 2008-12-25
AU2004309164A1 (en) 2005-07-14
CA2551038C (en) 2010-04-27
WO2005063754A1 (en) 2005-07-14
KR100854872B1 (ko) 2008-08-28
OA13347A (en) 2007-04-13
AP2331A (en) 2011-12-05
UY28693A1 (es) 2005-07-29
NL1027833C2 (nl) 2006-03-06
AR047340A1 (es) 2006-01-18
IL176349A0 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
PE20051051A1 (es) Compuestos de triazol como antagonistas de la vasopresina
PE20081374A1 (es) Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20051054A1 (es) Compuestos heterociclicos utiles como secretagogos de la hormona de crecimiento
PE20081409A1 (es) Antagonistas del receptor de progesterona
PA8631601A1 (es) Nuevos compuestos
TW200505903A (en) CGRP receptor antagonists
ATE537170T1 (de) Cgrp-rezeptorantagonisten
ATE411323T1 (de) Cgrp-rezeptorantagonisten
PE20060459A1 (es) DERIVADOS DE AMINO-5,5-DIFENILIMIDAZOLONA COMO INHIBIDORES DE LA ß-SECRETASA
PE20071136A1 (es) Derivados de anilina sustituida como antagonistas de la histamina h3
PE20060306A1 (es) Compuestos de heteroaril-amida sustituida
PE20060477A1 (es) Compuestos piperazinodionas como antagonistas del receptor de oxitocina
ECSP088240A (es) Composición de trazodona para administración una vez por día
ATE503755T1 (de) Cgrp-rezeptorantagonisten
ATE485269T1 (de) C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20090123A1 (es) Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo
ATE466860T1 (de) Cgrp-rezeptorantagonisten
EP1802372A4 (en) CGRP RECEPTOR ANTAGONISTS)
EP1856100A4 (en) CGRP RECEPTOR ANTAGONISTS
PE20081375A1 (es) Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
PE20060103A1 (es) Nuevas 5-acilindolinonas con contenido en cicloalquilo y su preparacion como medicamento
CY1111678T1 (el) Σταθεροποιημενες και διατηρημενες οφθαλμικες ενωσεις κετοτιφενης

Legal Events

Date Code Title Description
FC Refusal